Immutep Limited (NASDAQ:IMMP) Short Interest Up 5.1% in May

Immutep Limited (NASDAQ:IMMP) was the target of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 3,920,000 shares, a growth of 5.1% from the May 15th total of 3,730,000 shares. Based on an average daily trading volume, of 234,100 shares, the days-to-cover ratio is currently 16.7 days.

Analysts Set New Price Targets

Separately, Capital One Financial initiated coverage on Immutep in a research report on Friday, May 17th. They set an “overweight” rating and a $10.00 price target for the company.

Immutep Price Performance

IMMP traded down $0.04 during trading on Tuesday, hitting $2.65. 2,422 shares of the company’s stock were exchanged, compared to its average volume of 195,992. Immutep has a 1 year low of $1.58 and a 1 year high of $3.34. The stock has a 50 day moving average price of $2.74 and a 200 day moving average price of $2.49.

Institutional Trading of Immutep

A number of institutional investors have recently added to or reduced their stakes in the business. Meridian Wealth Management LLC lifted its position in shares of Immutep by 3.6% during the fourth quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock worth $774,000 after purchasing an additional 11,250 shares in the last quarter. PFG Investments LLC purchased a new position in shares of Immutep during the 1st quarter valued at approximately $119,000. BNP Paribas Financial Markets grew its position in shares of Immutep by 15.4% during the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after buying an additional 4,700 shares in the last quarter. Oracle Investment Management Inc. increased its stake in shares of Immutep by 9.4% in the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock worth $1,316,000 after buying an additional 48,449 shares during the last quarter. Finally, Virtu Financial LLC raised its holdings in Immutep by 269.4% in the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 32,864 shares in the last quarter. 2.32% of the stock is owned by hedge funds and other institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.